Biomarcadores en el líquido cefalorraquídeo de pacientes con deterioro cognitivo leve: metaanálisis de su capacidad predictiva para el diagnóstico de la enfermedad de Alzheimer

Monge-Argilés, J.A.; Sánchez‐Paya, José; Muñoz-Ruiz, Carlos; Pampliega-Pérez, A; Montoya, Jhon Williams; Leiva-Santana, C

doi:10.33588/rn.5004.2009163

Cited by 16 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Monge-Argilés et al (2010) indicated a mean sensitivity of 81% (95% CI = 72–88%), and a specificity of 87% (95% CI = 81–91%). Moreover, likelihood ratios show that this combination also has the best capacity to rule-in MCI-C patients (LR+ = 6) and to rule-out non-MCI-C patients (LR− = 0.2).…”

Section: Resultsmentioning

confidence: 98%

Meta-Review of CSF Core Biomarkers in Alzheimerâ€™s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Ferreira

Perestelo-Pérez²,

Westman

et al. 2014

Front. Aging Neurosci.

116

View full text Add to dashboard Cite

Background: Current research criteria for Alzheimer’s disease (AD) include cerebrospinal fluid (CSF) biomarkers into the diagnostic algorithm. However, spreading their use to the clinical routine is still questionable.Objective: To provide an updated, systematic and critical review on the diagnostic utility of the CSF core biomarkers for AD.Data sources: MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane Library, and CRD.Eligibility criteria: (1a) Systematic reviews with meta-analysis; (1b) Primary studies published after the new revised diagnostic criteria; (2) Evaluation of the diagnostic performance of at least one CSF core biomarker.Results: The diagnostic performance of CSF biomarkers is generally satisfactory. They are optimal for discriminating AD patients from healthy controls. Their combination may also be suitable for mild cognitive impairment (MCI) prognosis. However, CSF biomarkers fail to distinguish AD from other forms of dementia.Limitations: (1) Use of clinical diagnosis as standard instead of pathological postmortem confirmation; (2) variability of methodological aspects; (3) insufficiently long follow-up periods in MCI studies; and (4) lower diagnostic accuracy in primary care compared with memory clinics.Conclusion: Additional work needs to be done to validate the application of CSF core biomarkers as they are proposed in the new revised diagnostic criteria. The use of CSF core biomarkers in clinical routine is more likely if these limitations are overcome. Early diagnosis is going to be of utmost importance when effective pharmacological treatment will be available and the CSF core biomarkers can also be implemented in clinical trials for drug development.

show abstract

Section: Resultsmentioning

confidence: 98%

Meta-Review of CSF Core Biomarkers in Alzheimerâ€™s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Ferreira

Perestelo-Pérez²,

Westman

et al. 2014

Front. Aging Neurosci.

116

View full text Add to dashboard Cite

show abstract

“…Estos criterios actualizados [3,4] se basan en unas líneas de investigación bien fundamentadas, apoyadas en estudios epidemiológicos y anatomopatológicos [12]. Aún quedan abiertas nuevas perspectivas de líneas de investigación [10] relacionadas con la detección de marcadores biológicos [13,14] y con técnicas de neuroimagen [15] que puedan ayudar a esclarecer los aspectos más relevantes de cara a la detección y diagnóstico del DCL y de la demencia.…”

Section: Desarrollo Y Conclusionesunclassified

Deterioro cognitivo leve: detección temprana y nuevas perspectivas

Mora‐Simón¹,

García-García²,

Mv³

et al. 2012

RevNeurol

View full text Add to dashboard Cite

Introduction. Along past years, interest in mild cognitive impairment (MCI) research and its early detection has been increased. Unlike first theories, international current proposals suggest that MCI is a syndrome characterized by an impairment in one or more cognitive functions without interfering in daily functional abilities and it is also accompanied by a concern because of the cognitive change. Although early MCI detection is usually made by cognitive screening tests, most of them do not seem to correctly detect MCI, but dementia. Aim. To expose an analysis of the cognitive screening tests more suitable for clinical MCI detection, according to current researches. Development and conclusions. There are three kind of cognitive screening tests: general cognitive screening tests, specific cognitive screening tests and MCI-subtype cognitive screening test. We observe that most of the tests don't follow current MCI criteria. In this respect we propose to jointly apply tests, as well as the necessity of a carefully test choice to effectively detect MCI in clinical practice.

show abstract

“…As compared to the amyloid-beta, tau seems to be a reliable marker. Several studies have reported that elevated levels of total-tau and phosphorylated tau in the CSF correlate well with CI and progressing to dementias (Hansson et al, 2006;Diniz et al, 2008;Mattsson et al, 2009;Monge-Argilés et al, 2010;Olsson et al, 2016). As CI is associated with several neurological disorders establishing selective and specific blood-based biomarkers is challenging (Grundke- Iqbal et al, 1986).…”

Section: Introductionmentioning

confidence: 99%

Blood-Based Biomarkers for Predictive Diagnosis of Cognitive Impairment in a Pakistani Population

Iqbal

Braidy

Ahmed

2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Numerous studies have identified an association between age-related cognitive impairment (CI) and oxidative damage, accumulation of metals, amyloid levels, tau, and deranged lipid profile. There is a concerted effort to establish the reliability of these blood-based biomarkers for predictive diagnosis of CI and its progression. We assessed the serum levels of high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, total cholesterol, selected metals (Cu, Al, Zn, Pb, Mn, Cad), and total-tau and amyloid beta-42 protein in mild (n = 71), moderate (n = 86) and severe (n = 25) cognitively impaired patients and compared them with age-matched healthy controls (n = 90) from Pakistan. We found that a decrease in HDL cholesterol (correlation coefficient r = 0.467) and amyloid beta-42 (r = 0.451) were associated with increased severity of CI. On the other hand, an increase in cholesterol ratio (r = −0.562), LDL cholesterol (r = −0.428), triglycerides, and total-tau (r = −0.443) were associated with increased severity of CI. Increases in cholesterol ratio showed the strongest association and correlated with increases in tau concentration (r = 0.368), and increased triglycerides were associated with decreased amyloid beta-42 (r = −0.345). Increased Cu levels showed the strongest association with tau increase and increased Zn and Pb levels showed the strongest association with reduced amyloid beta-42 levels. Receiver Operating Characteristic (ROC) showed the cutoff values of blood metals (Al, Pb, Cu, Cad, Zn, and Mn), total-tau, and amyloid beta-42 with sensitivity and specificity. Our data show for the first time that blood lipids, metals (particularly Cu, Zn, Pb, and Al), serum amyloid-beta-42/tau proteins modulate each other's levels and can be collectively used as a predictive marker for CI.

show abstract

Biomarcadores en el líquido cefalorraquídeo de pacientes con deterioro cognitivo leve: metaanálisis de su capacidad predictiva para el diagnóstico de la enfermedad de Alzheimer

Cited by 16 publications

References 0 publications

Meta-Review of CSF Core Biomarkers in Alzheimerâ€™s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Meta-Review of CSF Core Biomarkers in Alzheimerâ€™s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

Deterioro cognitivo leve: detección temprana y nuevas perspectivas

Blood-Based Biomarkers for Predictive Diagnosis of Cognitive Impairment in a Pakistani Population

Contact Info

Product

Resources

About